Capitalising Notch Biomarkers in the Drug Development Market
(CAPNOTCH)
Start date: Sep 1, 2013,
End date: Aug 31, 2014
PROJECT
FINISHED
"CapNotch is the translation from discovery of multimodal cancer biomarkers of the Notch pathway to a strong market proposition. Biomarker products for validating specificity, efficacy and toxicity of preclinical compounds that target this pathway are highly wanted by academia and industry and could fuel progress in this area. One step further lays the opportunity to exploit such biomarkers for patient stratification and treatment monitoring, as well for advancing clinical trials as for supporting clinical decision making. The outcome of CapNotch should guide the selection of the most feasible proposition."
Get Access to the 1st Network for European Cooperation
Log In
or
Create an account
to see this content
Coordinator
UNIVERSITEIT MAASTRICHT
€ 150 000,00- Judith Doomen
- Minderbroedersberg 4-6 6200 MD MAASTRICHT (Netherlands)
Details
- 99.7% € 150 000,00
-
FP7-IDEAS-ERC
- Project on CORDIS Platform